These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34294923)

  • 1. Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study.
    Puurunen MK; Vockley J; Searle SL; Sacharow SJ; Phillips JA; Denney WS; Goodlett BD; Wagner DA; Blankstein L; Castillo MJ; Charbonneau MR; Isabella VM; Sethuraman VV; Riese RJ; Kurtz CB; Brennan AM
    Nat Metab; 2021 Aug; 3(8):1125-1132. PubMed ID: 34294923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of a synthetic live bacterial therapeutic for phenylketonuria with biosensor-enabled enzyme engineering.
    Adolfsen KJ; Callihan I; Monahan CE; Greisen PJ; Spoonamore J; Momin M; Fitch LE; Castillo MJ; Weng L; Renaud L; Weile CJ; Konieczka JH; Mirabella T; Abin-Fuentes A; Lawrence AG; Isabella VM
    Nat Commun; 2021 Oct; 12(1):6215. PubMed ID: 34711827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria.
    Isabella VM; Ha BN; Castillo MJ; Lubkowicz DJ; Rowe SE; Millet YA; Anderson CL; Li N; Fisher AB; West KA; Reeder PJ; Momin MM; Bergeron CG; Guilmain SE; Miller PF; Kurtz CB; Falb D
    Nat Biotechnol; 2018 Oct; 36(9):857-864. PubMed ID: 30102294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of phenylalanine ammonia lyase as an intracellularly free and extracellularly cell surface-immobilized enzyme on a gut microbe as a live biotherapeutic for phenylketonuria.
    Jiang Y; Sun B; Qian F; Dong F; Xu C; Zhong W; Huang R; Zhai Q; Jiang Y; Yang S
    Sci China Life Sci; 2023 Jan; 66(1):127-136. PubMed ID: 35907113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a synthetic biotic for treatment of phenylketonuria: a phase 2 clinical trial.
    Vockley J; Sondheimer N; Puurunen M; Diaz GA; Ginevic I; Grange DK; Harding C; Northrup H; Phillips JA; Searle S; Thomas JA; Zori R; Denney WS; Ernst SL; Humphreys K; McWhorter N; Kurtz C; Brennan AM
    Nat Metab; 2023 Oct; 5(10):1685-1690. PubMed ID: 37770764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood phenylalanine reduction reverses gene expression changes observed in a mouse model of phenylketonuria.
    Manek R; Zhang YV; Berthelette P; Hossain M; Cornell CS; Gans J; Anarat-Cappillino G; Geller S; Jackson R; Yu D; Singh K; Ryan S; Bangari DS; Xu EY; Kyostio-Moore SRM
    Sci Rep; 2021 Nov; 11(1):22886. PubMed ID: 34819582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria.
    Zori R; Thomas JA; Shur N; Rizzo WB; Decker C; Rosen O; Li M; Schweighardt B; Larimore K; Longo N
    Mol Genet Metab; 2018 Nov; 125(3):217-227. PubMed ID: 30146451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria.
    Charbonneau MR; Denney WS; Horvath NG; Cantarella P; Castillo MJ; Puurunen MK; Brennan AM
    Commun Biol; 2021 Jul; 4(1):898. PubMed ID: 34294862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM).
    Thomas J; Levy H; Amato S; Vockley J; Zori R; Dimmock D; Harding CO; Bilder DA; Weng HH; Olbertz J; Merilainen M; Jiang J; Larimore K; Gupta S; Gu Z; Northrup H;
    Mol Genet Metab; 2018 May; 124(1):27-38. PubMed ID: 29653686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up.
    Burton BK; Longo N; Vockley J; Grange DK; Harding CO; Decker C; Li M; Lau K; Rosen O; Larimore K; Thomas J;
    Mol Genet Metab; 2020 Aug; 130(4):239-246. PubMed ID: 32593547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study.
    Longo N; Zori R; Wasserstein MP; Vockley J; Burton BK; Decker C; Li M; Lau K; Jiang J; Larimore K; Thomas JA
    Orphanet J Rare Dis; 2018 Jul; 13(1):108. PubMed ID: 29973227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics, safety, tolerability and pharmacokinetics of a single oral dose of an engineered phenylalanine ammonia-lyase in patients with phenylketonuria.
    Fazio TN; Healy L; Heise T; Inwood A; Manolikos C; Rahman Y; Woerle HJ; Hendriksz CJ
    Mol Genet Metab Rep; 2023 Dec; 37():101012. PubMed ID: 38053938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial.
    Longo N; Harding CO; Burton BK; Grange DK; Vockley J; Wasserstein M; Rice GM; Dorenbaum A; Neuenburg JK; Musson DG; Gu Z; Sile S
    Lancet; 2014 Jul; 384(9937):37-44. PubMed ID: 24743000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redesign of an Escherichia coli Nissle treatment for phenylketonuria using insulated genomic landing pads and genetic circuits to reduce burden.
    Triassi AJ; Fields BD; Monahan CE; Means JM; Park Y; Doosthosseini H; Padmakumar JP; Isabella VM; Voigt CA
    Cell Syst; 2023 Jun; 14(6):512-524.e12. PubMed ID: 37348465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial.
    Harding CO; Amato RS; Stuy M; Longo N; Burton BK; Posner J; Weng HH; Merilainen M; Gu Z; Jiang J; Vockley J;
    Mol Genet Metab; 2018 May; 124(1):20-26. PubMed ID: 29628378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year interim safety and efficacy of pegvaliase in Japanese adults with phenylketonuria.
    Ishige M; Ito T; Hamazaki T; Kuwahara M; Lee L; Shintaku H
    Mol Genet Metab; 2023 Nov; 140(3):107697. PubMed ID: 37717412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic Control of Patients with Phenylketonuria in a Portuguese Metabolic Centre Comparing Three Different Recommendations.
    Kanufre V; Almeida MF; Barbosa CS; Carmona C; Bandeira A; Martins E; Rocha S; Guimas A; Ribeiro R; MacDonald A; Pinto A; Rocha JC
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34578995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetically engineered probiotic for the treatment of phenylketonuria (PKU); assessment of a novel treatment in vitro and in the PAHenu2 mouse model of PKU.
    Durrer KE; Allen MS; Hunt von Herbing I
    PLoS One; 2017; 12(5):e0176286. PubMed ID: 28520731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenylalanine ammonia lyase, enzyme substitution therapy for phenylketonuria, where are we now?
    Sarkissian CN; Gámez A
    Mol Genet Metab; 2005 Dec; 86 Suppl 1():S22-6. PubMed ID: 16165390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of phenylalanine on cognitive, cerebral, and neurometabolic parameters in adult patients with phenylketonuria (the PICO study): a randomized, placebo-controlled, crossover, noninferiority trial.
    Trepp R; Muri R; Abgottspon S; Bosanska L; Hochuli M; Slotboom J; Rummel C; Kreis R; Everts R
    Trials; 2020 Feb; 21(1):178. PubMed ID: 32054509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.